Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar Market Formation Isn't Going According To Plan

This article was originally published in The Pink Sheet Daily

Executive Summary

As user fee negotiations begin, FDA has far more sponsors in product development phase and far fewer marketing applications than anticipated.

You may also be interested in...



PDUFA Fees Forced Down For FY 2017 Due To Refund Provision

Final year of this user fee cycle will include 14% discount, but agency says it is ready for revenue reduction.

PDUFA Fees Forced Down For FY 2017 Due To Refund Provision

Final year of this user fee cycle will include 14% discount, but agency says it is ready for revenue reduction.

Biosimilar User Fee Negotiations Won't Start Until 2016

Mid-December kick-off meeting puts emerging user fee program on much later track than others.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS078099

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel